Wolverine Stack: BPC-157 + TB-500 Recovery Synergy

Why combine them

• BPC-157 — angiogenesis via VEGFR2, NO pathway, FGF/EGF activation.
• TB-500 — sequesters G-actin, promotes cell migration and progenitor differentiation.

Hypothesis: BPC creates the new vascular plumbing, TB-500 brings the cells to use it. Combination exceeds the sum of parts in animal models.

Studies on the combo

Combination-specific human literature is limited and mostly self-reported. Robust evidence comes from each compound separately in animal models.

Pre-mixed Wolverine: composition

Single vial: 10 mg BPC-157 + 10 mg TB-500 lyophilized together. Advantage: one reconstitution, one injection per dose.

Reconstitution

20 mg total + 2 mL BAC = 10 mg/mL total = 5 mg/mL of each peptide.

500 mcg BPC + 500 mcg TB-500 combined dose = 0.10 mL = 10 units U100.

Typical research ranges

Self-reported human programs: 250–500 mcg of each peptide, 1–2×/day SC, 4–6 weeks. Site near injury when possible.

Wolverine vs separate vials

When NOT to use

• Acute injuries with active bleeding (wait 24–72h).
• Known neoplastic mass — angiogenesis precaution.
• No baseline injury — minimal expected effect.